Mark L. Ormiston

3.6k total citations · 2 hit papers
39 papers, 2.3k citations indexed

About

Mark L. Ormiston is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Mark L. Ormiston has authored 39 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Immunology. Recurrent topics in Mark L. Ormiston's work include Pulmonary Hypertension Research and Treatments (14 papers), Angiogenesis and VEGF in Cancer (8 papers) and IL-33, ST2, and ILC Pathways (8 papers). Mark L. Ormiston is often cited by papers focused on Pulmonary Hypertension Research and Treatments (14 papers), Angiogenesis and VEGF in Cancer (8 papers) and IL-33, ST2, and ILC Pathways (8 papers). Mark L. Ormiston collaborates with scholars based in Canada, United Kingdom and United States. Mark L. Ormiston's co-authors include Stephen L. Archer, Thenappan Thenappan, John Ryan, Nicholas W. Morrell, Duncan J. Stewart, David W. Courtman, Mark Southwood, Stephen D. Moore, Lindsey G. Hawke and Lü Long and has published in prestigious journals such as Nature, The Lancet and Circulation.

In The Last Decade

Mark L. Ormiston

38 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pulmonary arterial hypertension: pathogenesis and clinical management

2018 676 citations Thenappan Thenappan, Mark L. Ormiston et al. BMJ profile →
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension

2015 347 citations Lü Long, Mark L. Ormiston et al. Nature Medicine profile →

Peers

Countries citing papers authored by Mark L. Ormiston

Since Specialization

Citations

This map shows the geographic impact of Mark L. Ormiston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Ormiston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Ormiston more than expected).

Fields of papers citing papers by Mark L. Ormiston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. Ormiston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Ormiston. The network helps show where Mark L. Ormiston may publish in the future.

Co-authorship network of co-authors of Mark L. Ormiston

This figure shows the co-authorship network connecting the top 25 collaborators of Mark L. Ormiston. A scholar is included among the top collaborators of Mark L. Ormiston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark L. Ormiston. Mark L. Ormiston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circular RNA Profiling Identifies circ5078 as a BMPR2 -Derived Regulator of Endothelial Proliferation and Stress Responses 2025 ·Arteriosclerosis Thrombosis and Vascular Biology ·(unknown), (unknown), Patrick Thompson, (unknown), (unknown), Jeffrey Mewburn, (unknown), Kimberly J. Dunham‐Snary, Anna R. Hemnes, Joy D. Cogan, Eric D. Austin, Rizwan Hamid, Stephen L. Archer, Neil Renwick, Mark L. Ormiston	1
2	IFN-β activates cytotoxic function of human natural killer cells toward IL-27 and poly(I:C) stimulated PC3 and DU145 cells 2023 ·Cellular Immunology ·(unknown), Lindsey G. Hawke, Mark L. Ormiston, Katrina Gee	1
3	Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics 2023 ·Cancers ·(unknown), Lindsey G. Hawke, Mark L. Ormiston	12
4	Evolving Concepts in Endothelial Pathobiology of Pulmonary Arterial Hypertension 2022 ·Hypertension ·Nicholas D Cober, (unknown), Mark L. Ormiston, Duncan J. Stewart	34
5	Monitoring the 5′UTR landscape reveals isoform switches to drive translational efficiencies in cancer 2022 ·Oncogene ·Ramona Weber, Umesh Ghoshdastider, Daniel Spies, (unknown), (unknown), (unknown), Mark L. Ormiston, Peter F. Renz, (unknown), (unknown), (unknown), Homare Yamahachi, Ataman Sendoel	26
6	The Production of Pro-angiogenic VEGF-A Isoforms by Hypoxic Human NK Cells Is Independent of Their TGF-β-Mediated Conversion to an ILC1-Like Phenotype 2020 ·Frontiers in Immunology ·Lindsey G. Hawke, (unknown), Mark L. Ormiston	20
7	A Potential Role for Exosomal Translationally Controlled Tumor Protein Export in Vascular Remodeling in Pulmonary Arterial Hypertension 2018 ·American Journal of Respiratory Cell and Molecular Biology ·Elisabet Ferrer, Benjamin J. Dunmore, (unknown), Mark L. Ormiston, Stephen D. Moore, John Deighton, Lü Long, Yang Xu, Duncan J. Stewart, Nicholas W. Morrell	34
8	Pulmonary arterial hypertension: pathogenesis and clinical management breakdown → 2018 ·BMJ ·Thenappan Thenappan, Mark L. Ormiston, John Ryan, Stephen L. Archer	676
9	A sex-specific reconstitution bias in the competitive CD45.1/CD45.2 congenic bone marrow transplant model 2017 ·Scientific Reports ·(unknown), Stephen D. Moore, Nicholas W. Morrell, Mark L. Ormiston	16
10	Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients 2017 ·Blood Coagulation & Fibrinolysis ·(unknown), (unknown), Mackenzie Bowman, Lindsey G. Hawke, (unknown), Jeffrey Mewburn, Mark L. Ormiston, (unknown), Donald H. Maurice, Paula James	31
11	MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype 2016 ·American Journal of Respiratory and Critical Care Medicine ·Zhigang Hong, (unknown), Asish Dasgupta, François Potus, Kimberly J. Dunham‐Snary, Sébastien Bonnet, Lian Tian, Jennifer Fu, Sandra Breuils‐Bonnet, Steeve Provencher, Danchen Wu, Jeffrey Mewburn, Mark L. Ormiston, Stephen L. Archer	136
12	Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2 +/− Mice with Schistosomiasis 2015 ·American Journal of Respiratory and Critical Care Medicine ·Alexi Crosby, Elaine Soon, Frances M. Jones, Mark Southwood, Leila Haghighat, Mark Toshner, Tim Raine, (unknown), Peiran Yang, Stephen D. Moore, Elisabet Ferrer, P.A. Wright, Mark L. Ormiston, R. James White, (unknown), David W. Dunne, Nicholas W. Morrell	20
13	Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood 2015 ·Journal of Visualized Experiments ·Mark L. Ormiston, Mark Toshner, Fedir N. Kiskin, (unknown), (unknown), Nicholas W. Morrell, Amer A. Rana	55
14	Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension breakdown → 2015 ·Nature Medicine ·Lü Long, Mark L. Ormiston, Xudong Yang, Mark Southwood, Stefan Gräf, Rajiv D. Machado, Matthias Müeller, Bernd Kinzel, Lai Ming Yung, Janine M. Wilkinson, Stephen D. Moore, Kylie M. Drake, Micheala A. Aldred, Paul B. Yu, Paul D. Upton, Nicholas W. Morrell	347
15	Proteomic Analysis Implicates Translationally Controlled Tumor Protein as a Novel Mediator of Occlusive Vascular Remodeling in Pulmonary Arterial Hypertension 2014 ·Circulation ·Jessie R. Lavoie, Mark L. Ormiston, Carol Perez‐Iratxeta, David W. Courtman, (unknown), Elisabet Ferrer, Paola Caruso, Mark Southwood, William S. Foster, Nicholas W. Morrell, Duncan J. Stewart	59
16	Transcript Analysis Reveals a Specific HOX Signature Associated with Positional Identity of Human Endothelial Cells 2014 ·PLoS ONE ·Mark Toshner, Benjamin J. Dunmore, Eoin McKinney, Mark Southwood, Paola Caruso, Paul D. Upton, J.P. Waters, Mark L. Ormiston, Jeremy N. Skepper, Gerard B. Nash, Amer A. Rana, Nicholas W. Morrell	51
17	Sixth Annual Scientific Workshops and Debates of the Pulmonary Vascular Research Institute (PVRI) 2013 ·Pulmonary Circulation ·(unknown), Magdalena Gierula, Frances M. Jones, Lan Zhao, (unknown), Beata Wójciak‐Stothard, Mark L. Ormiston	1
18	A Lymphocyte-Dependent Mode of Action for Imatinib Mesylate in Experimental Pulmonary Hypertension 2013 ·American Journal Of Pathology ·Mark L. Ormiston, Yupu Deng, Natalie T. Rundle, (unknown), James N. Tsoporis, Thomas G. Parker, Duncan J. Stewart, David W. Courtman	12
19	Late outgrowth endothelial progenitor cells engineered for improved survival and maintenance of function in transplant-related injury 2011 ·Transplant International ·Jing Zhao, Eleanor M. Bolton, Mark L. Ormiston, J. Andrew Bradley, Nicholas W. Morrell, Andrew Lever	5
20	MRI characterization of agarose gel micro-droplets at acute time-points within the rabbit lumbar muscle 2008 ·Biomaterials ·Warren D. Foltz, Mark L. Ormiston, Duncan J. Stewart, David W. Courtman, Alexander Dick	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact